Liposomal Medications Come of Age

Abstract

Dr. Gevirtz is Associate Professor of Anesthesiology, Louisiana State University Health Sciences Center, New Orleans, LA, and Medical Director, Somnia Pain Management, 627 West St, Harrison, New York, NY 10528; E-mail: [email protected]. The author and all staff in a position to control the content of this CME activity and their spouses/life partners (if any) have disclosed that they have no financial relationships with, or financial interests in, any commercial organizations pertaining to this educational activity. Dr. Gevirtz has disclosed that the U.S. Food and Drug Administration has not approved the use of liposomal morphine and liposomal bupivacaine for the treatment of chronic pain as discussed in off-label use in this article. Please consult the products’ labeling for approved information. Lippincott Continuing Medical Education Institute, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Lippincott Continuing Medical Education Institute, Inc., designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. To earn CME credit, you must read the CME article and complete the quiz and evaluation assessment survey on the enclosed form, answering at least 70% of the quiz questions correctly. This activity expires on December 31, 2014.